Cancer BiologybioRxivPreprint
Preclinical Prediction of Resistance and Optimization of Sequential Therapy for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors
Yuki Takei, Hirotaka Kuroiwa, Chisaki Arai…·Kentaro Semba
This study predicts resistance mutations to next-generation ALK inhibitors and evaluates sequential therapy strategies for ALK-positive lung cancer.
DOI 10.1101/2025.05.26.656085